Risultati per: Screening del cancro al seno nelle donne

Da incontro Donne Protagoniste in Sanità appello per il settore

Chiu et al recently investigated the long-term effectiveness of national faecal immunochemical test (FIT) screening for colorectal cancer (CRC).1 They demonstrated reduced risk of advanced-stage CRC and its mortality with larger reductions in distal CRC as compared with proximal CRC. An additional outcome of the CRC screening programme may be early detection of other diseases, such as inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). The prevalence of IBD is up to 1% in westernised countries.2 3 However, symptoms of IBD vary and may increase time to diagnosis.4 Correct and early diagnosis is important to improve treatment outcomes and patients’ quality of life.5 Although early markers of IBD, such as antimicrobial antibodies and serum proteins, are emerging,6 7 colonoscopy still remains one of the only methods to detect early IBD. Since…

New England Journal of Medicine, Volume 387, Issue 23, Page 2126-2137, December 2022.

Annals of Internal Medicine, Volume 175, Issue 12, Page JC140, December 2022.

Nearly a quarter of physicians do not believe that a patient’s life expectancy should be a metric for halting cancer screening, despite guidelines that recommend against routine cancer screening when life expectancy is less than 10 years. What’s more, less than half of physicians are convinced the overscreening is a major problem among older adults.

Annals of Internal Medicine, Ahead of Print.

Presentato il 5/o Rapporto di Cittadinanzattiva e Federfarma

This review examines the current FDA regulatory process for artificial intelligence products used in breast cancer screening and suggests system improvements.

This cohort study assesses the association of prostate-specific antigen screening with incidence of metastatic prostate cancer in the Veterans Health Administration (VHA) from 2005 to 2019.

Appello da 4 campionesse per praticarlo anche nella terza e quarta età

Incontro nella Asl 1 di Roma con medici, dirigenti, ricercatori

Circulation, Volume 146, Issue 22, Page 1730-1732, November 29, 2022.

In squadra con Atena Donna. “Voliamo lontano dalla violenza”

Dati studio Iss in spot trasmesso su Reti Rai

Introduction
Colonoscopy quality can vary depending on endoscopist-related factors. Quality indicators, such as adenoma detection rate (ADR), have been adopted to reduce variations in care. Several interventions aim to improve ADR, but these fall into several domains that have traditionally been difficult to compare. We will conduct a systematic review and network meta-analysis of randomised controlled trials evaluating the efficacies of interventions to improve colonoscopy quality and report our findings according to clinically relevant interventional domains.

Methods and analysis
We will search MEDLINE (Ovid), PubMed, EMBASE, CINAHL, Web of Science, Scopus and Evidence-Based Medicine from inception to September 2022. Four reviewers will screen for eligibility and abstract data in parallel, with two accordant entries establishing agreement and with any discrepancies resolved by consensus. The primary outcome will be ADR. Two authors will independently conduct risk of bias assessments. The analyses of the network will be conducted under a Bayesian random-effects model using Markov-chain Monte-Carlo simulation, with 10 000 burn-ins and 100 000 iterations. We will calculate the ORs and corresponding 95% credible intervals of network estimates with a consistency model. We will report the impact of specific interventions within each domain against standard colonoscopy. We will perform a Bayesian random-effects pairwise meta-analysis to assess heterogeneity based on the I2 statistic. We will assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework for network meta-analyses.

Ethics and dissemination
Our study does not require research ethics approval given the lack of patient-specific data being collected. The results will be disseminated at national and international gastroenterology conferences and peer-reviewed journals.

PROSPERO registration number
CRD42021291814.